Abeona shares retain Buy rating H.C. Wainwright sees approval potential for pz-cel in RDEB
ABEO Stock | USD 5.47 0.02 0.37% |
About 56% of Abeona Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Abeona Therapeutics suggests that many traders are alarmed. Abeona Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Abeona Therapeutics. Many technical investors use Abeona Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Abeona |
Abeona shares retain Buy rating H.C. Wainwright sees approval potential for pz-cel in RDEB
Read at investing.com
Abeona Therapeutics Fundamental Analysis
We analyze Abeona Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Abeona Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Abeona Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Outstanding
Shares Outstanding Comparative Analysis
Abeona Therapeutics is currently under evaluation in shares outstanding category among its peers. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Abeona Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Abeona Therapeutics stock to make a market-neutral strategy. Peer analysis of Abeona Therapeutics could also be used in its relative valuation, which is a method of valuing Abeona Therapeutics by comparing valuation metrics with similar companies.
Peers
Abeona Therapeutics Related Equities
PDSB | PDS Biotechnology | 9.21 | ||||
ADAP | Adaptimmune Therapeutics | 5.17 | ||||
RGNX | Regenxbio | 5.05 | ||||
BDTX | Black Diamond | 3.28 | ||||
ANEB | Anebulo Pharmaceuticals | 3.25 | ||||
INZY | Inozyme Pharma | 2.82 | ||||
RVPH | Reviva Pharmaceuticals | 2.79 | ||||
MREO | Mereo BioPharma | 2.09 | ||||
ATHA | Athira Pharma | 1.92 | ||||
ACAD | ACADIA Pharmaceuticals | 1.74 | ||||
CABA | Cabaletta Bio | 1.27 | ||||
DAWN | Day One | 1.51 | ||||
CKPT | Checkpoint Therapeutics | 1.73 | ||||
AFMD | Affimed NV | 2.00 | ||||
FBIO | Fortress Biotech | 2.79 | ||||
IVVD | Invivyd | 4.88 | ||||
TERN | Terns Pharmaceuticals | 6.28 | ||||
LPTX | Leap Therapeutics | 8.77 | ||||
XFOR | X4 Pharmaceuticals | 10.81 |
Check out Abeona Therapeutics Hype Analysis, Abeona Therapeutics Correlation and Abeona Therapeutics Performance. To learn how to invest in Abeona Stock, please use our How to Invest in Abeona Therapeutics guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abeona Therapeutics. If investors know Abeona will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abeona Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Abeona Therapeutics is measured differently than its book value, which is the value of Abeona that is recorded on the company's balance sheet. Investors also form their own opinion of Abeona Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Abeona Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abeona Therapeutics' market value can be influenced by many factors that don't directly affect Abeona Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abeona Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abeona Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abeona Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.